VTGN - ビスタジェン・セラピュ―ティクス (VistaGen Therapeutics Inc.)

VTGNのニュース

   Analysts Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $330,000.00  2021/12/04 09:12:41 Dakota Financial News
Equities research analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to announce $330,000.00 in sales for the current quarter, Zacks reports. Two analysts have made estimates for VistaGen Therapeutics earnings, with estimates ranging from $300,000.00 to $360,000.00. VistaGen Therapeutics reported sales of $310,000.00 during the same quarter last year, which would suggest a positive year over year []
   Renaissance Technologies LLC Buys Shares of 102,641 VistaGen Therapeutics, Inc. (NASDAQ:VTGN)  2021/11/26 09:36:45 Transcript Daily
Renaissance Technologies LLC bought a new position in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) in the 2nd quarter, Holdings Channel reports. The fund bought 102,641 shares of the companys stock, valued at approximately $323,000. A number of other institutional investors have also recently made changes to their positions in VTGN. Xponance Inc. bought a new []
   State Street Corp Purchases Shares of 3,059,610 VistaGen Therapeutics, Inc. (NASDAQ:VTGN)  2021/11/25 10:24:41 Dakota Financial News
State Street Corp acquired a new stake in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,059,610 shares of the companys stock, valued at approximately $9,638,000. State Street Corp owned 1.59% of VistaGen Therapeutics as of []
   Nuveen Asset Management LLC Invests $2.16 Million in VistaGen Therapeutics, Inc. (NASDAQ:VTGN)  2021/11/24 09:34:41 Dakota Financial News
Nuveen Asset Management LLC acquired a new position in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 686,380 shares of the companys stock, valued at approximately $2,163,000. A number of other institutional investors have also modified their []
   $330,000.00 in Sales Expected for VistaGen Therapeutics, Inc. (NASDAQ:VTGN) This Quarter  2021/11/23 01:42:41 Dakota Financial News
Equities analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report sales of $330,000.00 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for VistaGen Therapeutics earnings, with estimates ranging from $300,000.00 to $360,000.00. VistaGen Therapeutics posted sales of $310,000.00 during the same quarter last year, which suggests a positive year over year growth []
   VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021  2021/07/09 12:30:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in the ‘Updates in Neuropsych’ panel at the virtual William Blair Biotech Focus Conference 2021 on July 15, 2021 at 9:00 a.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.
   What Do VistaGens Newly Added Risk Factors Mean for Investors  2021/07/09 10:54:31 Smarter Analyst
VistaGen Therapeutics (VTGN) is a biopharmaceutical company developing medicines targeting several nervous system disorders. On June 29, the company released its Fiscal 2021 The post What Do VistaGens Newly Added Risk Factors Mean for Investors appeared first on Smarter Analyst .
   VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors  2021/07/07 12:30:00 Intrado Digital Media
Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders
   VistaGen Therapeutics Insights: Return On Capital Employed  2021/07/06 17:51:52 Benzinga
During Q4, VistaGen Therapeutics ''s (NASDAQ: VTGN ) reported sales totaled $441.90 thousand. Despite a 17.36% in earnings, the company posted a loss of $6.22 million. In Q3, VistaGen Therapeutics brought in $313.60 thousand in sales but lost $5.30 million in earnings. Why ROCE Is Significant Changes in earnings and sales indicate shifts in VistaGen Therapeutics''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is Full story available on Benzinga.com
   VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow  2021/06/30 18:33:58 Seeking Alpha
   Analysts Top Healthcare Picks: Iovance Biotherapeutics (IOVA), VistaGen Therapeutics (VTGN)  2021/05/31 07:56:30 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Iovance Biotherapeutics (IOVA), VistaGen Therapeutics The post Analysts Top Healthcare Picks: Iovance Biotherapeutics (IOVA), VistaGen Therapeutics (VTGN) appeared first on Smarter Analyst .
   William Blair Upgrades VistaGen Therapeutics (VTGN) to Buy  2021/05/28 15:45:37 Smarter Analyst
In a report issued on May 26, Tim Lugo from William Blair upgraded VistaGen Therapeutics (VTGN) to Buy. The companys shares closed last The post William Blair Upgrades VistaGen Therapeutics (VTGN) to Buy appeared first on Smarter Analyst .
   VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder  2021/05/26 00:00:00 BioSpace
VistaGen Therapeutics Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the initiation of its PALISADE Phase 3 clinical program with the PALISADE-1 Phase 3 trial,
   VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B  2021/05/26 13:28:54 Benzinga
VistaGen Therapeutics Inc (NASDAQ: VTGN ) has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Full story available on Benzinga.com
   VistaGen initiates late-stage trial of PH94B in social anxiety disorder  2021/05/26 12:36:34 Seeking Alpha

calendar